Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2016) 5 P159 | DOI: 10.1530/boneabs.5.P159

Cell biology: osteoblasts and bone formation

Osteogenic superiority of bone marrow-derived osteoblastic cells (ALLOB®) over bone marrow-derived mesenchymal stromal cells

Sandra Pietri, Hélène Dubout, Sabrina Ena, Candice Hoste & Enrico Bastianelli

14 views


Bone Therapeutics S.A., Gosselies, Belgium.


Bone therapeutics is a bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair, more specifically in non-union and delayed-union fractures where the bone repair process is impaired. The company has developed a unique allogeneic osteoblastic cell product (ALLOB®) derived from bone marrow which is currently tested in humans in the indication of delayed-union fractures. The purpose of the study was to directly compare ALLOB® vs non-differentiated mesenchymal stromal cells (MSC) for their in vitro osteogenic characteristics and their in vivo osteogenic potential in order to determine which cellular type would be the most adapted for bone fracture repair.

Methods: Healthy volunteers’ bone marrow aspirates (n=6) were expanded (i) into BM-MSCs using a complete MSC culture medium or (ii) into ALLOB® cells according to its manufacturing process. Cells were characterized in vitro by morphology, immunophenotype, gene expression using RNAseq technology and their differentiation potential. Additionally, their osteogenic potential was assessed in vivo in the calvaria bone formation model in nude mice (n=6 per group).

Results: The in vitro side-by-side comparison studies showed that although ALLOB® and BM-MSC shared some common general characteristics such as the three minimal MSC Dominici’s criteria, ALLOB® expressed significantly higher levels of chondro/osteoblastic genes such as BMP2 (fold change (FC) >100), ALPL (FC>12), CBFA1 (FC>3) and differentiated significantly earlier than BM-MSC toward the osteogenic lineage. Moreover, the bone formation model in nude mice demonstrated that used at the same cellular concentration, ALLOB® was able to induce significantly more (160 vs 107%) bone formation than BM-MSC (118 vs 107%) only 2 weeks after administration.

Conclusion: Our side-by-side comparison studies demonstrated that in vitro and in vivo, ALLOB® displays superior osteogenic capacity to BM-MSC and is therefore a better candidate for the treatment of bone fractures.

Volume 5

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.